Matthew Kraman
Overview
Explore the profile of Matthew Kraman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
2346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraman M, Faroudi M, Allen N, Kmiecik K, Gliddon D, Seal C, et al.
Clin Cancer Res
. 2020 Apr;
26(13):3333-3344.
PMID: 32299814
Purpose: Although programmed death-ligand 1 (PD-L1) antibody-based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy. FS118 is a novel bispecific,...
2.
Everett K, Kraman M, Wollerton F, Zimarino C, Kmiecik K, Gaspar M, et al.
Methods
. 2018 Sep;
154:60-69.
PMID: 30208333
The immunoglobulin superfamily protein lymphocyte-activation gene 3 (LAG-3) participates in immune suppression and has been identified as a suitable target for cancer therapies. In order to generate bispecific antibodies targeting...
3.
Arnold J, Magiera L, Kraman M, Fearon D
Cancer Immunol Res
. 2014 Apr;
2(2):121-6.
PMID: 24778275
The depletion of tumor stromal cells that are marked by their expression of the membrane protein fibroblast activation protein-α (FAP) overcomes immune suppression and allows an anticancer cell immune response...
4.
Varadkar P, Despres D, Kraman M, Lozier J, Phadke A, Nagaraju K, et al.
Dev Dyn
. 2014 Jan;
243(6):778-90.
PMID: 24425002
Background: Protein Phosphatase 2A (PP2A) function is controlled by regulatory subunits that modulate the activity of the catalytic subunit and direct the PP2A complex to specific intracellular locations. To study...
5.
Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D, et al.
Proc Natl Acad Sci U S A
. 2013 Nov;
110(50):20212-7.
PMID: 24277834
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. Despite finding that PDA-bearing mice had cancer cell-specific CD8(+) T...
6.
Roberts E, Deonarine A, Jones J, Denton A, Feig C, Lyons S, et al.
J Exp Med
. 2013 May;
210(6):1137-51.
PMID: 23712428
Fibroblast activation protein-α (FAP) identifies stromal cells of mesenchymal origin in human cancers and chronic inflammatory lesions. In mouse models of cancer, they have been shown to be immune suppressive,...
7.
Bannard O, Kraman M, Fearon D
J Immunol
. 2010 Nov;
185(12):7141-5.
PMID: 21068412
Persistent viral infections induce the differentiation and accumulation of large numbers of senescent CD8(+) T cells, raising the possibility that repetitive stimulation drives clones of T cells to senesce. It...
8.
Kraman M, Bambrough P, Arnold J, Roberts E, Magiera L, Jones J, et al.
Science
. 2010 Nov;
330(6005):827-30.
PMID: 21051638
The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was first identified in human...
9.
Bannard O, Kraman M, Fearon D
Eur J Immunol
. 2009 Jul;
39(8):2083-7.
PMID: 19637204
CD8(+) T-cell responses must have at least two components, a replicative cell type that proliferates in the secondary lymphoid tissue and that is responsible for clonal expansion, and cytotoxic cells...
10.
Varadkar P, Kraman M, McCright B
Genesis
. 2009 Jun;
47(8):573-8.
PMID: 19530136
The Notch pathway is an intercellular signaling mechanism frequently used for controlling cell fate during organogenesis. There are four structurally related Notch receptors in mice and humans, and Notch1 and...